dapagliflozin has been researched along with Glycosuria* in 2 studies
2 other study(ies) available for dapagliflozin and Glycosuria
| Article | Year |
|---|---|
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
A new class of potent and highly selective SGLT2 inhibitors is disclosed. Compound 31 (HSK0935) demonstrated excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of 843-fold. It showed robust urinary glucose excretion in Sprague-Dawley (SD) rats and affected more urinary glucose excretion in Rhesus monkeys. Finally, an efficient synthetic route has been developed featuring a ring-closing cascade reaction to incorporate a double ketal 1-methoxy-6,8-dioxabicyclo[3.2.1]octane ring system. Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; CHO Cells; Cricetulus; Diabetes Mellitus, Type 2; Glucose; Glycosuria; Humans; Hypoglycemic Agents; Kidney; Macaca mulatta; Male; Mice, Inbred ICR; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
A series of novel O-spiroketal C-arylglucosides have been prepared and evaluated in cell-based functional assays for activity against human sodium-dependent glucose co-transporters 1 and 2 (SGLT1 and 2). The core spiro[isobenzofuran-1,2'-pyran] structure proved to be an effective scaffold for diversification and a number of compounds with single digit nanomolar potency and high selectivity have been synthesized. Compound 5a promoted glucosuria when administered in vivo in rats and produced a significant blood glucose reduction effect. Topics: Animals; Benzofurans; Blood Glucose; Glucosides; Glycosuria; Humans; Pyrans; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Spiro Compounds | 2009 |